AEON Biopharma, Inc.
AEON · AMEX
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $597 | $1,064 | $825 | $3,037 |
| G&A Expenses | $0 | $0 | $0 | $0 |
| SG&A Expenses | $1,933 | $3,258 | $3,125 | $2,629 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | -$37 | $16 | -$3,488 | -$3,345 |
| Operating Expenses | $2,493 | $4,338 | $462 | $2,321 |
| Operating Income | -$2,493 | -$4,338 | -$462 | -$2,321 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | -$2,045 | -$2,304 | $9,557 | $4,403 |
| Pre-Tax Income | -$4,538 | -$6,642 | $9,095 | $2,082 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$4,538 | -$6,642 | $9,095 | $2,082 |
| % Margin | – | – | – | – |
| EPS | -0.39 | -0.6 | 2.28 | 3.76 |
| % Growth | 35% | -126.3% | -39.4% | – |
| EPS Diluted | -0.39 | -0.6 | 2.28 | 3.47 |
| Weighted Avg Shares Out | 11,634 | 11,070 | 3,984 | 600 |
| Weighted Avg Shares Out Dil | 11,635 | 11,091 | 3,985 | 555 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $19 | $20 | $19 | $23 |
| EBITDA | -$2,511 | -$4,302 | -$3,931 | -$5,643 |
| % Margin | – | – | – | – |